Qiao Han, Feng Yan, Tang Huaping
Department of Respiratory Medicine, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Transl Cancer Res. 2021 Oct;10(10):4514-4522. doi: 10.21037/tcr-21-2002.
Collagen type VI alpha 6 chain (COL6A6) plays a vital role in maintaining cell structural integrity and regulating cell function. It has been proven to be a tumor suppressor gene and molecular therapeutic target. However, the mechanism of COL6A6 in non-small cell lung cancer (NSCLC) has not been elucidated. The purpose of this study was to investigate the relationship between COL6A6 and NSCLC.
We analyzed the expression of COL6A6 in NSCLC using public databases and verified the findings in NSCLC tissues and cells. The protein expression of COL6A6 was evaluated by Western blot. The CCK8 and Transwell assays were used to assess the invasion ability of NSCLC cells after COL6A6 knockdown. At the same time, we discussed the role of the JAK signalling pathway that may be related to COL6A6.
Bioinformatics analysis showed that COL6A6 expression was downregulated in NSCLC, and its high expression was associated with a better prognosis of NSCLC. , the expression of COL6A6 in NSCLC tissues was significantly lower than that in adjacent tissues. Furthermore, COL6A6 knockout accelerated the proliferation, invasion, and migration of NSCLC cells and activated the JAK signalling pathway.
Our study illustrates that COL6A6 is a tumor suppressor gene in NSCLC and is involved in NSCLC tumorigenesis by regulating the JAK signalling pathway. Therefore, COL6A6 holds promise as a molecular therapeutic target for NSCLC.
VI型胶原蛋白α6链(COL6A6)在维持细胞结构完整性和调节细胞功能方面发挥着至关重要的作用。它已被证明是一种肿瘤抑制基因和分子治疗靶点。然而,COL6A6在非小细胞肺癌(NSCLC)中的作用机制尚未阐明。本研究的目的是探讨COL6A6与NSCLC之间的关系。
我们使用公共数据库分析了COL6A6在NSCLC中的表达,并在NSCLC组织和细胞中验证了研究结果。通过蛋白质免疫印迹法评估COL6A6的蛋白表达。使用CCK8和Transwell实验评估COL6A6敲低后NSCLC细胞的侵袭能力。同时,我们讨论了可能与COL6A6相关的JAK信号通路的作用。
生物信息学分析表明,COL6A6在NSCLC中的表达下调,其高表达与NSCLC的较好预后相关。此外,COL6A6在NSCLC组织中的表达明显低于相邻组织。此外,COL6A6基因敲除加速了NSCLC细胞的增殖、侵袭和迁移,并激活了JAK信号通路。
我们的研究表明,COL6A6是NSCLC中的一种肿瘤抑制基因,通过调节JAK信号通路参与NSCLC的肿瘤发生。因此,COL6A6有望成为NSCLC的分子治疗靶点。